Palatin Technologies Inc (PTN): Cash & Equivalents
$2.56M
As of 2025-06-30
$10.16M
As of 2026-03-31
-55.9%
3-year compound annual growth
-50.1%
5-year compound annual growth
-21.1%
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-06-30 | $2.56M | -73.1% | 2025-09-23, Balance as of period end |
| 2024-06-30 | $9.53M | -13.2% | 2024-09-30, Balance as of period end |
| 2023-06-30 | $10.98M | -63.3% | 2023-09-28, Balance as of period end |
| 2022-06-30 | $29.94M | -50.2% | 2022-09-22, Balance as of period end |
| 2021-06-30 | $60.10M | -27.5% | 2022-09-22, Balance as of period end |
| 2020-06-30 | $82.85M | +90.4% | 2021-09-28, Balance as of period end |
| 2019-06-30 | $43.51M | +14.5% | 2020-09-25, Balance as of period end |
| 2018-06-30 | $38.00M | -5.5% | 2020-09-25, Balance as of period end |
| 2017-06-30 | $40.20M | +402.3% | 2020-09-25, Balance as of period end |
| 2016-06-30 | $8.00M | -70.7% | 2018-09-13, Balance as of period end |
| 2015-06-30 | $27.30M | +124.0% | 2017-09-25, Balance as of period end |
| 2014-06-30 | $12.18M | -36.4% | 2016-09-19, Balance as of period end |
| 2013-06-30 | $19.17M | +400.8% | 2015-09-18, Balance as of period end |
| 2012-06-30 | $3.83M | -79.7% | 2014-09-12, Balance as of period end |
| 2011-06-30 | $18.87M | +249.1% | 2013-09-27, Balance as of period end |
| 2010-06-30 | $5.41M | n/a | 2012-09-10, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Palatin Technologies Inc (PTN) | 2025-06-30 | $2.56M | -73.1% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare PTN, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗